Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Stomatitis 1Neuroendocrine Tumors 1Neoplasms 1Mucositis 1Mouth Neoplasms 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × RRx-001 × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03515538 2024-11-04

PREVLAR

EpicentRx, Inc.

Phase 2 Completed
53 enrolled 15 charts
Head & NeckOther

Head and Neck Neoplasms, Mouth Neoplasms, Stomatitis, Mucositis

NCT01359982 2024-11-01

DINAMIC

EpicentRx, Inc.

Phase 1 Completed
26 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasms

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed
62 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated
4 enrolled 6 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡